ArticleLeukemia & lymphoma2022

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.

Theodoros Karantanos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.